GeneDx Holdings (WGS) Cash & Equivalents (2020 - 2026)

GeneDx Holdings has disclosed Cash & Equivalents across 7 years of filings, most recently posting $93.9 million for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 5.8% year-over-year to $93.9 million; the TTM figure through Mar 2026 stood at $93.9 million (down 5.8% YoY), while the FY2025 annual figure was $105.0 million, up 23.22% from the prior year.
• Cash & Equivalents retreated to $93.9 million in Q1 2026, from $105.0 million in the prior quarter.
• Over the last five years, Cash & Equivalents for WGS reached as high as $315.0 million in Q1 2022 and fell as low as $56.1 million in Q2 2024.
• The 5-year median for Cash & Equivalents is $99.7 million (2023), against an average of $130.1 million.
• The widest YoY moves for Cash & Equivalents: up 973.92% in 2022, down 69.06% in 2022.
• A 5-year view of Cash & Equivalents shows it stood at $123.9 million in 2022, then dropped by 19.57% to $99.7 million in 2023, then retreated by 14.52% to $85.2 million in 2024, then increased by 23.22% to $105.0 million in 2025, then fell by 10.55% to $93.9 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $93.9 million, $105.0 million, and $96.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.